Full-Strength Anxiolytic & Beta-Blocker
Each tablet contains Clonazepam 0.5 mg and Propranolol 20 mg with precision content uniformity and consistent dissolution kinetics complying with Indian Pharmacopoeia standards.
DELOTRIL-PRO-0.5 (also designated as DELOTRIL PRO) is a potent dual-action neuropsychiatric tablet uniting Clonazepam IP 0.5 mg with Propranolol Hydrochloride IP 20 mg by Blessme, Dellwich Lifescience LLP. Formulated for moderate-to-severe panic disorder, agoraphobia, and intense autonomic panic storms by extinguishing central fear cascades while eliminating adrenaline-driven tachycardia and tremors.

Detailed pharmaceutical specifications, active API monograph compliance, full-strength somatic synergy, and 20x10 blister packaging details for DELOTRIL-PRO-0.5.
DELOTRIL-PRO-0.5 combines 0.5 mg Clonazepam with 20 mg Propranolol. Designed for moderate-to-severe panic disorder where profound psychological terror is coupled with terrifying physical palpitations, rapid pulse, and trembling.
In-depth pharmacological evaluation of Clonazepam IP 0.5 mg + Propranolol HCl IP 20 mg tablets, marketed as DELOTRIL-PRO-0.5 (DELOTRIL PRO) by Blessme (Dellwich Lifescience LLP). Covers somatic panic cascades, cardiac protection, and pharmaceutical supply across India.
DELOTRIL-PRO-0.5 is a full-strength dual-action neuropsychiatric tablet formulated to treat patients suffering from debilitating panic disorder and somatic distress. The combination addresses both ends of the panic reflex: the central nervous system trigger and the autonomic cardiovascular execution.
When doctors and hospitals search for Clonazepam Propranolol 0.5 20 tablet or medicine for severe panic attacks with tachycardia, they require proven content uniformity and reliable release kinetics. DELOTRIL-PRO-0.5 delivers these qualities through automated clean-room manufacturing under WHO-GMP compliance.
Approved neurological and psychiatric indications for DELOTRIL-PRO-0.5 include:
Clonazepam 0.5 mg provides high occupancy of central GABAA receptor complexes in the amygdalo-hippocampal circuitry. By amplifying chloride ion conductance, it produces potent hyperpolarization that stops acute catastrophic thoughts and anticipatory dread.
Simultaneously, Propranolol 20 mg competitively occupies beta-1 adrenergic receptors on cardiac pacemakers and myocytes, preventing epinephrine from elevating heart rate and contractile force. This halts bounding tachycardia, cold sweats, and hyperventilation, eliminating the physical alarm signals that typically escalate panic into a clinical emergency.
Clinical criteria for selecting between the formulations:
DELOTRIL-PRO-0.5 must be taken strictly in accordance with medical advice:
DELOTRIL-PRO-0.5 contains Clonazepam, which carries potential for tolerance and habit formation with prolonged therapy. Contraindicated in patients with asthma, COPD, severe bradycardia, or high-degree AV block. Dispensed strictly against a valid medical prescription.
DELOTRIL-PRO-0.5 is manufactured in WHO-GMP certified facilities adhering to Schedule M protocols, ensuring micro-blend homogeneity and maximum packaging stability.
Each tablet contains Clonazepam 0.5 mg and Propranolol 20 mg with precision content uniformity and consistent dissolution kinetics complying with Indian Pharmacopoeia standards.
High-barrier blister packaging protects sensitive tablets from ambient moisture and light degradation, ensuring long-term shelf stability across tropical environments.
Every batch is backed by authenticated Certificates of Analysis (COA), disintegration profiles, assay validation data, and Material Safety Data Sheets for hospital audits.
Produced in state-of-the-art accredited manufacturing units in Gujarat adhering to automated compression, online check-weighing, and Good Laboratory Practices (GLP).
Prescribing guidance, contraindications, and drug interactions for Clonazepam 0.5 mg + Propranolol 20 mg tablets.
DELOTRIL-PRO-0.5 is a Schedule H prescription drug. Not for OTC sale. Do not consume alcohol during therapy. Exercise caution when driving or operating machinery.
Approved neurological and psychiatric indications for DELOTRIL-PRO-0.5:
Key contraindications and monitoring requirements:
Dellwich Lifescience LLP is an established pharmaceutical company based in Science City, Ahmedabad, Gujarat, dedicated to advanced formulation technology, uncompromising quality assurance, and ethical healthcare supply. Through our specialized neurology division, Blessme, we manufacture and market superior neuro-psychiatric treatments, including DELOTRIL-PRO-0.5 (Clonazepam 0.5 mg + Propranolol 20 mg Tablets).
We support PCD pharma franchise partners, hospital supply chains, and contract manufacturing clients across India with guaranteed supply security, validated product dossiers, and prompt dispatch.
Whether you are seeking DELOTRIL-PRO-0.5 for district monopoly PCD franchise distribution, third-party contract manufacturing, or hospital bulk procurement, Dellwich Lifescience LLP delivers dependable supply and competitive trade margins.
Secure district-level monopoly marketing rights for DELOTRIL-PRO-0.5 and the Blessme neuropsychiatry range with visual aids, product glossaries, and promotional input support.
Turnkey manufacturing solutions for pharmaceutical marketing companies with flexible batch runs, rapid production turnaround, and full regulatory dossier support from Ahmedabad.
Direct bulk pharmaceutical supply agreements for multispecialty hospital chains, psychiatric nursing homes, and institutional medical tenders with prompt pan-India logistics.
When sourcing Clonazepam Propranolol tablets in India, DELOTRIL-PRO-0.5 by Blessme provides exceptional clinical efficacy, reliable 20x10 blister packaging, and comprehensive B2B franchise support.
Manufactured in accredited facilities using IP grade APIs, ensuring exact active content uniformity and fast disintegration.
Tamper-evident, moisture-resistant blister strips protect tablets from ambient humidity and transport friction.
Direct factory dispatch with GST invoicing, verified batch COA, and dependable logistics coverage across all Indian states.
Exclusive district-level franchise rights for DELOTRIL-PRO-0.5 and the Blessme portfolio with promotional visual aids.
Certificates of Analysis (COA), stability testing data, and MSDS readily available for institutional audits and tenders.
Direct access to Dellwich Lifescience product specialists for quick quotes, customized bulk orders, and customer assistance.
Authoritative answers to clinical, commercial, dosage, and regulatory questions regarding Clonazepam + Propranolol tablets.
DELOTRIL-PRO-0.5 is a fixed-dose combination oral tablet manufactured under the Blessme neuropsychiatry division of Dellwich Lifescience. It contains Clonazepam IP 0.5 mg (a high-potency benzodiazepine anxiolytic) and Propranolol Hydrochloride IP 20 mg (a non-selective beta-blocker).
DELOTRIL-PRO-0.5 is preferred when the patient experiences moderate-to-severe panic attacks, debilitating psychological anxiety, or agoraphobia requiring full 0.5 mg Clonazepam central fear reduction alongside the 20 mg Propranolol somatic cardiac control. DELOTRIL-PRO-0.25 is reserved for milder situational panic or when minimal sedation is desired.
The Propranolol component begins moderating heart rate and tremors within 30 to 60 minutes. Clonazepam exerts marked central calming and panic relief within 45 to 60 minutes, with peak therapeutic effect reached within 1 to 2 hours post-dose.
DELOTRIL-PRO-0.5 is packed in 20x10 blister strips (200 tablets per box) with an indicative catalog MRP of ₹62.00 per strip of 10 tablets, offering an affordable, high-quality option for long-term patient compliance.
Yes. Due to the 0.5 mg Clonazepam content, mild-to-moderate sedation, drowsiness, and lightheadedness can occur, particularly during initial days of therapy. Patients should avoid driving, operating heavy machinery, or engaging in hazardous tasks until tolerance develops.
Abrupt discontinuation after continuous therapy can cause severe rebound anxiety, insomnia, tremors, and rebound tachycardia due to unmasked beta-adrenergic receptors and benzodiazepine withdrawal. Discontinuation must always follow a supervised tapering protocol.
No. Propranolol is a non-selective beta-blocker that blocks beta-2 receptors in the lungs, which can precipitate bronchospasm in asthmatic or COPD patients. It is strictly contraindicated in this patient population.
Yes. DELOTRIL-PRO-0.5 can be taken with or without food. Taking it with meals may reduce potential mild gastrointestinal upset. Consistent timing each day is recommended.
Both Clonazepam and Propranolol cross the placenta and carry potential risks to the developing fetus. DELOTRIL-PRO-0.5 should not be used in pregnancy unless deemed essential by a specialist physician.
Alcohol is strictly prohibited. Combining alcohol with Clonazepam significantly increases the risk of severe central nervous system depression, respiratory arrest, profound hypotension, and coma.
DELOTRIL-0.5 MD contains solely Clonazepam 0.5 mg in a fast-dissolving mouth dissolving tablet form. DELOTRIL-PRO-0.5 contains Clonazepam 0.5 mg combined with 20 mg Propranolol HCl, providing dual central and cardiovascular autonomic coverage.
Pharma stockists and distributors can complete the enquiry form below or contact our business development executive directly on WhatsApp at +91 99099 31992 to secure exclusive district marketing rights.
We offer flexible MOQ options tailored to brand requirements with complete testing, artwork assistance, packaging design, and timely dispatch from our Gujarat facility.
Dellwich Lifescience LLP is located on Science City Road, Ahmedabad, Gujarat, India, with an established distribution network spanning all states across India.
Connect directly with Dellwich Lifescience LLP for trade pricing, district monopoly PCD rights, third-party manufacturing, or institutional hospital tender supplies.
Get wholesale pricing, PCD franchise monopoly rights, and technical documentation for Clonazepam 0.5mg + Propranolol 20mg Tablets.